US 12,109,301 B2
Formulations, methods, and systems for treating genitourinary conditions
Xiang Li, Brookline, MA (US); Michael J. Cima, Winchester, MA (US); and Brian H. Eisner, Needham, MA (US)
Assigned to Massachusetts Institute of Technology, Cambridge, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed by Massachusetts Institute of Technology, Cambridge, MA (US); and The General Hospital Corporation, Boston, MA (US)
Filed on Nov. 15, 2022, as Appl. No. 18/055,595.
Application 18/055,595 is a division of application No. 16/605,092, granted, now 11,523,985, previously published as PCT/US2018/027474, filed on Apr. 13, 2018.
Claims priority of provisional application 62/485,594, filed on Apr. 14, 2017.
Prior Publication US 2023/0083710 A1, Mar. 16, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 31/4409 (2006.01); A61K 31/4422 (2006.01); A61K 45/06 (2006.01)
CPC A61K 9/0034 (2013.01) [A61K 9/0002 (2013.01); A61K 31/4409 (2013.01); A61K 31/4422 (2013.01); A61K 45/06 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A formulation for local administration to a ureter of a patient, the formulation comprising:
a therapeutic agent selected from a calcium channel blocker, a rho kinase inhibitor, or a combination thereof; and
one or more pharmaceutically acceptable excipients,
wherein the formulation is suitable for local administration into the ureter, the formulation is configured to delay passage of the formulation from the ureter, and the formulation is in the form of a liquid solution or a viscous vehicle.